Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
Month: March 2023
Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical…
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today…
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) today…
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Topline Data Expected in 2Q 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023…
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation
Topline Data Expected in 2Q 2023 SEATTLE, Wash. and VANCOUVER, British Columbia, March 29, 2023…
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT),…
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial…
Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs
BOTHELL, Wash., March 29, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) reports financial…
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the…
QIAGEN’s QIAxcel Connect wins Red Dot design award
International design competition recognizes high-resolution DNA or RNA capillary electrophoresis instrument // QIAxcel marks the…
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least…
Poland and U.K. Regulatory Authorities – URPL and MHRA – Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study
Third generation drug substance manufacturing process increases the final yield of nomacopan by at least…
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net…
Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need
Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net…
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
PETACH TIKVA, Israel, March 29, 2023 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”),…